




Corporate Presentation

January 2026



Bioscience applied to the skin.

Legal Disclaimers

This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, current and future commercialization activities (including payer coverage), timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, timing of submissions and our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment, and potential market opportunities.

Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics, including our lead product candidates roflumilast cream and roflumilast foam; the progress of patient enrollment and dosing in our clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations, development and commercialization of our product candidates; the timing of submissions and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve

those markets; our commercialization, marketing and manufacturing capabilities and strategy; current and future agreements with third parties in connection with the commercialization of our product candidates; the timing and our ability to obtain and maintain quality payer coverage; the management of gross-to-net; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, gross-to-net, capital requirements and needs for additional financing. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC), as well as any subsequent filings.

Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Any forward-looking statement that we make in this presentation or

the accompanying oral presentation are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of such statement. Except as required by law, we undertake no obligation to revise or update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

For further information with respect to Arcutis, we refer you to our most recent annual report on Form 10-K, as amended, and our most recent quarterly report on Form 10-Q, filed with the SEC. In addition, we are subject to the information and reporting requirements of the Securities Exchange Act of 1934 and, accordingly, we file periodic reports, current reports, proxy statements and other information with the SEC. These periodic reports, current reports, proxy statements and other information are available for review at the SEC's website at <http://www.sec.gov>.

All product and company names are trademarks™ or registered® trademarks of their respective holders.

Our Strategy to Sustain Near- and Long-term Growth

Grow current ZORYVE business

- Conversion from topical steroids
- PCP / peds expansion
- Indication expansion / data generation

Expand ZORYVE into new markets

- 40+ case reports across various diseases
- Multiple POC studies in development or underway

Build our pipeline

- ARQ-234 for atopic dermatitis
- Potential external sources of innovation

2025: Strong Revenue Growth and Significant Progress

Key Commercial Highlights

First nine months 2025, net product revenue: **\$244.6 mm (+152% YoY)**

Steady demand growth: **+92% TRx YoY¹**

Growing market share: **~45% share² of branded topical TRx**



#1 NST across three approved indications³

R&D and Regulatory Achievements

- ✓ ZORYVE topical foam 0.3% approved for PsO in adults and adolescents 12 years of age and older
- ✓ ZORYVE cream 0.05% approved for AD in children ages 2 to 5 years old
- ✓ Submitted sNDA for ZORYVE cream 0.3% for PsO in children ages 2 to 5; PDUFA June 29, 2026
- ✓ Initiated Phase 2 proof-of-concept studies with ZORYVE foam 0.3% in vitiligo and hidradenitis suppurativa
- ✓ Completed enrollment in Phase 2 INTEGUMENT-INFANT of ZORYVE cream 0.05% in infants with AD
- ✓ Submitted IND application for ARQ-234

¹ Q3'25 year-on-year volume growth

² 44% share of branded topicals volume in plaque psoriasis, atopic dermatitis, seborrheic dermatitis Q3'25

³ Across plaque psoriasis, atopic dermatitis, and seborrheic dermatitis

NST=non-steroidal topical; TRx = total prescriptions; PsO = psoriasis; AD = atopic dermatitis; sNDA = supplemental New Drug Application; PDUFA = Prescription Drug User Fee Act

Value-Driving Catalysts Through 1Q27

CLINICAL AND REGULATORY DEVELOPMENTS

Initiate Phase 1 trial of ARQ-234	Atopic dermatitis	Q1 2026	○
Topline data for ZORYVE cream 0.05% in infants	Atopic dermatitis	Q1 2026	○
Submit sNDA for ZORYVE cream 0.05% in infants	Atopic dermatitis	Q3 2026	○
sNDA PDUFA for ZORYVE cream 0.3% in ages 2-5	Plaque psoriasis	June 29, 2026	○
Advancement decision for ZORYVE foam 0.3% incl. Ph2 data	Vitiligo	Q4 2026	○
Advancement decision for ZORYVE foam 0.3% incl. Ph2 data	Hidradenitis suppurativa	Q1 2027	○


COMMERCIAL PROGRESS

Achieve 2026 net products sales of \$455-470 million	2026	○
~20% expansion of dermatology sales force	1H 2026	○

FINANCIAL

Maintain quarterly cash flow break even	2026	○
---	------	---

Capital Allocation Strategy



Financial Highlights

\$191.4 million

Cash, cash equivalents and marketable securities (Sep. 30, 2025)

\$108.5 million

Total debt, net (Sep. 30, 2025)

Achieved sustainable cash flow breakeven

Capital Allocation Priorities

Grow current ZORYVE franchise

Expand ZORYVE into new markets through potential additional indications

Build pipeline with the advancement of ARQ-234 and potentially through external innovation

ZORYVE's Compelling Profile

01

Pleotropic MOA
and variety of
formulations
enabling breadth
of applications

02

Efficacious with
rapid onset of
symptom relief

03


Safety and tolerability
profile enabling
sustained use for
chronic conditions



Backdrop of **increasing scrutiny** on prolonged use of topical corticosteroids



Market for ZORYVE in Dermatology Specialty is Significant and Obtainable



Total Addressable Market: 30M patients
diagnosed across PsO, AD, and SD

Serviceable Addressable Market: 19M patients
receiving topical prescription, all specialties


Serviceable Obtainable Market: 8M patients
receiving topical prescription, dermatology
specialty

**Substantial patient population currently
receiving topical Rx in dermatology
specialty targeted by Arcutis sales force**




Substantial Growth Opportunity Remains as Segment Expansion Continues to be Driven by ZORYVE

Volume Growth Last 6 Quarters




TCS Effectively Flat vs Significant NST and ZORYVE Growth

Share of Dermatology Topical Rx



Sizeable Base of TCS Scripts Still to be Converted

R-4 Week TRx Share




ZORYVE Rx Share Continuously Increasing

Data Source: IQVIA Xponent Sales Data

¹Total topical market prescriptions of Arcutis targets for the four quarters Q1 2024 - Q4 2024; Branded Non-Steroidal Topicals (NSTs) includes ZORYVE, VTAMA, Opzelura, and Eucrisa

R-4=rolling 4 week; TRx=total prescriptions; TCS=topical corticosteroids; NST=non-steroidal topicals; PsO=plaque psoriasis; Seb Derm=seborrheic dermatitis; AD=atopic dermatitis; Rx=prescriptions

Steady TRx Growth for ZORYVE Portfolio through Q3 – Reaching ~17,500 Weekly TRx (Rolling 4-Week Basis)



TRx Growth

	vs. Q2'25	vs. Q3'24
Q3'25	+13%	+92%

Q3 2025 Financial Results

\$ Millions, Except Net Loss Per Share	Q3 2025	GAAP Reported		Q2 2025	QoQ Change
		Q3 2024	YoY Change		
Product Revenues, Net	\$99.2	44.8	122%	\$81.5	22%
Other Revenues	0.0	0.0	-	0.0	-
Total Revenues	\$99.2	44.8	122%	\$81.5	22%
Cost of Sales	8.7	5.5	58%	7.5	16%
R&D Expense	19.6	19.5	1%	19.5	1%
SG&A Expense	62.4	58.8	6%	69.2	-10%
Total Operating Expense	90.7	83.8	8%	96.1	-6%
Net Profit / (Loss)	7.4	(41.5)	-	(15.9)	-
Net Profit / (Loss) Per Share – Diluted	0.06	(0.33)	-	(0.13)	-

Figures may not tie due to rounding

Growing Concerns on Adverse Effects Driving Changes in Clinical Practice



Adopted in August 2025 by the SDPA Board of Directors and signed on August 20, 2025

The Society of Dermatology Physician Assistants (SDPA) recognizes emerging evidence on potential adverse effects associated with prolonged topical corticosteroid use in managing inflammatory dermatoses...the SDPA advocates for routine assessment of cumulative steroid exposure as a cornerstone of patient care.



Adopted on August 25, 2025 by the SDNP Board of Directors

The Society of Dermatology Nurse Practitioners (SDNP) recognizes the emerging evidence regarding the potential adverse effects of prolonged topical corticosteroid use in the management of chronic inflammatory dermatoses...the SDNP acknowledges the growing role of advanced topical targeted therapies that reduce reliance on chronic topical steroid use.




ZORYVE has the Profile to Displace Topical Corticosteroids

	Efficacious and Fast Acting	Broad MOA	Safety and Tolerability	Duration and Location of Use
TCS				
ZORYVE				

Increasing HCP appreciation of risks associated with sustained TCS use




Targeting Most Valuable PCP/Peds Prescribers Enables Efficient Commercial Footprint





Growth Strategy Will Increase Size of Obtainable Market and ZORYVE Share



Total Addressable Market: 30M patients
diagnosed across PsO, AD, and SD

Serviceable Addressable Market: 19M patients
receiving topical prescription, all specialties

Serviceable Obtainable Market: 17M patients
receiving topical prescription in dermatology, PCP,
and pediatric specialties



Our Label Expansion Efforts Aim to Progress ZORYVE for the Treatment of Pediatric Patients

01

- ZORYVE cream 0.05% for treatment of **atopic dermatitis patients ages 2-5** approved October '25
- New Ph3 INTEGUMENT-OLE data highlight long-term safety and durable efficacy, including long-term disease control with twice weekly dosing*

02

- Enrollment complete in INTEGUMENT-INFANT evaluating ZORYVE cream 0.05% in **atopic dermatitis patients ages 3-24 months**
- Brisk enrollment highlights high interest in alternative to TCS for infant atopic dermatitis patients

03

- sNDA for ZORYVE cream 0.3% for **Ps0 patients ages 2 to 5** years old submitted September '25 with PDUFA June '26
- If approved, would provide patients and caregivers important alternative to topical steroids and vitamin-D analogs





Data Generation Strategy is Cost Effective Approach to Further Establish ZORYVE's Position in Current Indications

			
	Palmoplantar psoriasis	Nail psoriasis	Scarring alopecias
Core Co-morbidity	Psoriasis	Psoriasis	Seb derm
Description	<ul style="list-style-type: none"> 12-16% of Ps0 patients have palmoplantar involvement Treated with topical steroids, systemics for severe & refractory palmoplantar Ps0 	<ul style="list-style-type: none"> A common manifestation of psoriasis affecting the nail matrix and nail bed Under-treated, treated by topical steroid injection, cosmetic cover-up, or systemic tx 	<ul style="list-style-type: none"> Group of 12 hair-loss & scarring disorders*; mostly CCCA (~85%) and LPP (~5%) No approved drugs; topical and injectable steroids with off-label anti-inflammatory drugs
U.S. Dx Prevalence	~1.1 – 1.4M patients	~3 – 5M patients**	~0.5 – 1.5M patients

*The 12 disorders include FM, LPP, Brocq, PCAS, FD, CCCA, EPD, DLE, FFA, GLS, AKN, KFSD

** Based on 40 – 50% manifestation rate at any given point within psoriasis patients

Images from WebMD, Medical News Today, Scarring Alopecia Foundation

Dx = diagnosis; Ps0 = psoriasis; tx = treatment; CCCA = commercial coverage, contracting, access; LPP = long-term patient persistence

Select Examples of ZORYVE Case Reports in Palmoplantar and Nail Psoriasis

Palmoplantar Psoriasis Treatment with Topical Roflumilast 0.3%

Diego Ruiz Dasilva MD, FAAD
Forefront Dermatology, Hampton, VA, USA




Successful Treatment of Nail Psoriasis with Topical Roflumilast: A Case Report

Leah A Johnston and Susan M Poelman



ZORYVE Pleiotropic Mechanism of Action



ROFLUMILAST

PDE4 inhibition modulates:

- Th1/Th2/Th17 cytokine expression
- Immune dysregulation
- Keratinocyte function
- Sensory neuron signaling
- Melanocyte stimulation


The specific mechanism(s) by which roflumilast exerts its therapeutic action is not well defined.

Proof of Concept Studies Will Inform Clinical Development for Further ZORYVE Label Expansions



Published Case Reports of ZORYVE Efficacy in Other Diseases

Palmo-plantar pustulosis	Nickel-induced allergic contact dermatitis
Scrotal pruritus	Chronic cutaneous lupus
Cutaneous lupus erythematosus	Scalp folliculitis
Recalcitrant discoid lupus erythematosus	Folliculitis decalvans
Drug-induced pruritus	Neurodermatitis of the scalp
Granuloma annulare	Recalcitrant pediatric facial vitiligo
Lichen planus	Erythema annulare centrifugum
Lichen nitidus	Polymorphous light eruptions
Lichen planus pigmentosus	Hailey-Hailey disease
Lichen sclerosis	Porokeratosis
Keratoderma	



Case Studies Produced by Clinicians Suggest Broad Benefits of ZORYVE Pleotropic MOA

Off-label Treatment of Chronic Cutaneous Lupus with Tacrolimus 0.1% Ointment and Roflumilast 0.3% Cream: A Split Face Comparison Case Study
Tracey Brown-Maher, MD



Case Report of Hailey-Hailey Disease Successfully Treated with Topical Roflumilast 0.3% Cream
Edward Klepper, MS, PA-C, et al.



Neurodermatitis of the Scalp Associated with Trichotillomania Treated with Roflumilast Cream 0.3%
Edith Hanna, MD and Nour El Moussawi, MD




Vitiligo is a Sizable and Under-Penetrated Market

Vitiligo

Vitiligo patient epidemiology flow, U.S. (2025)

Millions of people



Types of Vitiligo

Non-segmental




Segmental



- Vitiligo is a chronic skin disorder where areas of the skin lose their pigment
 - Non-segmental: progress rapidly for 1-2 years and then stabilize
 - Segmental: progress slowly
- While treatment options for vitiligo patients are limited, **about 75% of these patients receive treatment** with topical medications (i.e., corticosteroids or calcineurin inhibitors) and **about 50% receive a branded non-steroidal topical**
- **Poor satisfaction with available therapies** impacts patient willingness to pursue treatment

Large Undiagnosed HS Population Exists in the U.S., Creating High Opportunity Well Suited for Topical Rx

Hidradenitis Suppurativa



Hidradenitis Suppurativa



- Hidradenitis suppurativa (HS) is a **chronic, recurrent, and inflammatory skin condition** that causes painful nodules, abscesses, and tunnels
- Diagnosis and **treatment rates remain low because options are limited**, and effectiveness often does not last
- Beyond Stage I, a **sizeable Stage II-III population likely remains undiagnosed**

Note: ¹Figures reflect 2023 U.S. patients only; ²Prevalence based on HS diagnosis code of ICD-10 L73.2 over a 5+ year period (2016 - 23) as used by Moonlake 2023 analysis likely includes patients seen once by a physician for HS over a multi-year period; ³30K treated with biologics.; ⁴61K on Humira, other biologics, targeted treatments
 Source: Epidemiology reports for companies targeting HS and other dermatology disorders; academic publications; company reports; Treatment Survival in Patients With Hidradenitis Suppurativa, JEADV.

Emerging Evidence of ZORYVE Efficacy in Vitiligo and Hidradenitis Suppurativa

Recalcitrant Pediatric Facial Vitiligo Successfully Treated with Roflumilast Cream 0.3% Once Daily


By KELLY WARREN, MD, and SOFIA SANCHEZ, BA. | DR. WARREN and MS. SANCHEZ with Derm Texas in Dallas Texas | J CLIN AESTHET DERMATOL. 2025;(1):52-54

Treatment of Hidradenitis Suppurativa with Topical Roflumilast over 30 Days

Photos courtesy of Adam Friedman, MD, FAAD; George Washington University




HCP Adoption of ZORYVE Across Indications Accelerates Overall Penetration Substantially



ARQ-234 Mechanism of Action

Checkpoint Agonism

Our Target: The CD200 Axis



- **CD200 and its receptor CD200R** are membrane glycoproteins containing two Ig-like domains
- **CD200 axis** plays a role in both innate and adaptive immune cells
- **CD200** is widely expressed on tissues; its only (human) receptor, **CD200R1**, is expressed on immune effector cells
- **CD200R1 signaling** reduces immune activation for T cells, ILC2 cells, and myeloid cells, and decreases secretion of pro-inflammatory cytokines

Key differentiation from existing immune therapies:

- **CD200R1 activation** is inflammation resolving rather than immunosuppressive
- **Agonist intervention**, not a blockade mechanism